title: Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial.
abstract: Current guidelines advocate no treatment for patients with histologically mild hepatitis C virus (HCV) infection. This was a UK multicentre randomized controlled trial comparing alpha-interferon (3 MU thrice weekly) + ribavirin (1000-1200 mg/day) for 48 weeks with no treatment in treatment naive, adult patients with histologically mild chronic HCV infection. The aim was to compare benefits, safety and efficacy of combination therapy with alpha-interferon 2b and ribavirin for 48 weeks with no treatment (current standard management) in this patient group. In the treatment group 32 of 98 (33%) patients achieved a sustained virological response (SVR). Patients infected with genotype 1 had a lower SVR than those infected with genotype non-1 (18% vs 49% P = 0.02). No patients who failed to achieve a 2-log drop in viral load at 12 weeks achieved SVR. Improvements in quality of life 24 weeks postcessation of therapy compared with baseline using the SF-36 questionnaire measures were observed in the treated group. For patients with mild HCV infection with viral genotype non-1, the results are sufficiently good to suggest that therapeutic decisions should no longer be biopsy-driven. For patients infected with genotype 1, a liver biopsy is still indicated as the low chance of SVR is outweighed by an unacceptable burden of side-effects. Patients who fail to respond by 12 weeks of therapy should have their treatment curtailed early.
authors.affiliation: Hepatology Section, St Mary's Hospital, Imperial College London, London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Wright
authors.forename: D
authors.initials: D
authors.lastname: Forton
authors.forename: J
authors.initials: J
authors.lastname: Main
authors.forename: R
authors.initials: R
authors.lastname: Goldin
authors.forename: E
authors.initials: E
authors.lastname: Torok
authors.forename: R
authors.initials: R
authors.lastname: Tedder
authors.forename: P
authors.initials: P
authors.lastname: Grant
authors.forename: M
authors.initials: M
authors.lastname: Thursz
authors.forename: N
authors.initials: N
authors.lastname: Naoumov
authors.forename: C
authors.initials: C
authors.lastname: Millson
authors.forename: P R
authors.initials: PR
authors.lastname: Mills
authors.forename: M
authors.initials: M
authors.lastname: Bassendine
authors.forename: H C
authors.initials: HC
authors.lastname: Thomas
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000523:psychology / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin